NP at his best:

"We are humbled by the outpouring of inquiries and requests for access to leronlimab and are working around the clock with our many partners to facilitate access to a potential therapeutic benefit for COVID-19 patients."

The COVID-19 story also highlights the huge potential for the leronlimab pneumonia indication with the market of well over 3 million cases annually and mortality rate for severe cases of about 20% (common for people over 65). Pneumonia is also the leading cause of death for children under 5.